Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
Open Access
- 5 November 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (11), 1-6
- https://doi.org/10.1038/s41408-018-0136-x
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemiaTherapeutic Advances in Hematology, 2017
- Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling PathwaysClinical Infectious Diseases, 2017
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic LeukemiaThe Journal of Immunology, 2017
- Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibBlood, 2016
- Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemiaOncotarget, 2016
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibBlood, 2015
- Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose MetabolismPublished by The American Association of Immunologists ,2015
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapyHaematologica, 2014
- Blood leukocytes and macrophages of various phenotypes have distinct abilities to form podosomes and to migrate in 3D environmentsEuropean Journal of Cell Biology, 2012
- Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteriaProceedings of the National Academy of Sciences, 2004